N/A N=40 A More Physiological Feeding Process in ICU:the Intermittent Infusion With Semi-solidification of Nutrients
Nutrition, Enteral
Primary: the Ratio of the Enteral Nutrition — 0.98; 0.73 ratio
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=243 AR101 Real-World Open-Label Extension Study
Peanut Allergy
Primary: Number of Participants With Treatment-Emergent Adverse Events (Safety and Tolerability) — 219; 176; 43; 0 Participants
N/A N=16 Effect of an EAA/Whey Composition on Protein Metabolism
Sarcopenia
Primary: Protein Anabolism — 3.56; 11.8; 3.02 grams — p=<0.05
N/A N=27 Effects of Echo-optimization of Left Ventricular Assist Devices on Functional Capacity (VAFRACT)
Heart Failure
Primary: VO2 Peak — 13.2; 13.8; 14.2; 13.2 mL/Kg/min
N/A N=99 A Multicenter Randomized Trial Comparing IM Nails and Plate Fixation in Proximal Tibial Fractures
Tibial Fractures
Primary: Participants' Quality of Life at 3 Months — 0.60; 0.59 score on a scale
N/A N=138 A Usability Assessment of Naloxone by Community Members
Drug Overdose
Primary: Successful Administration of Naloxone — 32; 41; 46 Participants
N/A N=120 Jewel ACL Post Market Clinical Follow Up Study
Anterior Cruciate Ligament Injuries
Primary: Occurrence of Re-ruptures — 5; 1 Participants
N/A N=3 Acceptance and Commitment Therapy for Older Adults
Psychological Distress · Anxiety · Depression
Primary: Change in Quality of Life Assessed Using the Older People's Quality of Life Questionnaire (OPQOL-brief). — 43.33 score on a scale
Phase 3 N=506 Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)
Peanut Allergy
Primary: Frequency of Treatment Emergent Adverse Events, Including Serious Adverse Events — 334; 159; 171; 110 Participants
Phase 2 N=21 Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
MSS · RAS-mutant Colorectal Cancer
Primary: Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) — 1; 2 Participants
Phase 1 N=42 Hypertrophic Regression With N-Acetylcysteine in HCM
Hypertrophic Cardiomyopathy
Primary: Recruitment as Assessed by Number of Participants Who Enrolled to the Study — 29; 13 Participants
N/A N=37 EndoRotor DEN (Direct Endoscopic Necrosectomy)Trial
Acute Pancreatic Necrosis · Acute Pancreatitis · Necrotizing Pancreatitis
Primary: Safety: Number of Participants With Device Related Complications — 0 Participants
Phase 2 N=11 Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children
Hematogenously Acquired Staphylococcus Aureus Osteomyelitis · Bone Infection · Osteomyelitis
Primary: Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to Adverse Events (AEs) — 1 incidence
Early Phase 1 N=44 Comparison of the Cosmetic Effects of Bakuchiol and Retinol
Wrinkle · Photoaging
Primary: Change in Wrinkle Appearance — 19.0; 23.2 percentage of reduced fine wrinkles
Phase 2 N=38 A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndromes · Secondary Acute Myeloid Leukemia (AML)
Primary: Percentage of Participants With Overall Response — 13; 25 percentage of participants